HOYA Valuation

Is 7741 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 7741 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 7741 (¥20935) is trading below our estimate of fair value (¥21368.23)

Significantly Below Fair Value: 7741 is trading below fair value, but not by a significant amount.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 7741?

Other financial metrics that can be useful for relative valuation.

7741 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue8.3x
Enterprise Value/EBITDA24.7x
PEG Ratio3.2x

Price to Earnings Ratio vs Peers

How does 7741's PE Ratio compare to its peers?

The above table shows the PE ratio for 7741 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average30.5x
7747 Asahi Intecc
41.7x11.7%JP¥658.4b
8086 Nipro
23.7x12.1%JP¥228.3b
7730 Mani
29.3x9.2%JP¥184.5b
7780 Menicon
27.1x17.1%JP¥128.2b
7741 HOYA
37.2x11.6%JP¥7.3t

Price-To-Earnings vs Peers: 7741 is expensive based on its Price-To-Earnings Ratio (37.2x) compared to the peer average (30.5x).


Price to Earnings Ratio vs Industry

How does 7741's PE Ratio compare vs other companies in the JP Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a13.6%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a13.6%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 7741 is expensive based on its Price-To-Earnings Ratio (37.2x) compared to the JP Medical Equipment industry average (17.3x).


Price to Earnings Ratio vs Fair Ratio

What is 7741's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

7741 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio37.2x
Fair PE Ratio33.5x

Price-To-Earnings vs Fair Ratio: 7741 is expensive based on its Price-To-Earnings Ratio (37.2x) compared to the estimated Fair Price-To-Earnings Ratio (33.5x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 7741 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentJP¥20,935.00
JP¥22,850.00
+9.1%
8.7%JP¥26,000.00JP¥19,200.00n/a14
Nov ’25JP¥20,485.00
JP¥22,600.00
+10.3%
8.4%JP¥26,000.00JP¥19,200.00n/a14
Oct ’25JP¥20,055.00
JP¥22,244.23
+10.9%
8.3%JP¥26,000.00JP¥19,200.00n/a13
Sep ’25JP¥20,595.00
JP¥22,155.36
+7.6%
8.5%JP¥26,000.00JP¥19,200.00n/a14
Aug ’25JP¥18,680.00
JP¥21,861.54
+17.0%
7.6%JP¥24,500.00JP¥19,200.00n/a13
Jul ’25JP¥18,570.00
JP¥21,553.85
+16.1%
6.5%JP¥24,000.00JP¥19,000.00n/a13
Jun ’25JP¥19,060.00
JP¥21,169.23
+11.1%
6.0%JP¥23,000.00JP¥19,000.00n/a13
May ’25JP¥18,435.00
JP¥20,796.15
+12.8%
6.6%JP¥23,000.00JP¥18,500.00n/a13
Apr ’25JP¥18,830.00
JP¥20,454.17
+8.6%
6.1%JP¥22,500.00JP¥18,500.00n/a12
Mar ’25JP¥19,935.00
JP¥20,496.15
+2.8%
6.2%JP¥22,500.00JP¥18,500.00n/a13
Feb ’25JP¥18,550.00
JP¥19,457.69
+4.9%
10.1%JP¥22,000.00JP¥15,050.00n/a13
Jan ’25JP¥17,625.00
JP¥18,204.55
+3.3%
12.7%JP¥22,000.00JP¥14,400.00n/a11
Dec ’24JP¥16,465.00
JP¥17,662.50
+7.3%
10.7%JP¥21,000.00JP¥14,400.00n/a12
Nov ’24JP¥15,120.00
JP¥17,745.83
+17.4%
11.1%JP¥21,000.00JP¥14,400.00JP¥20,485.0012
Oct ’24JP¥15,325.00
JP¥18,154.55
+18.5%
9.3%JP¥21,000.00JP¥16,000.00JP¥20,055.0011
Sep ’24JP¥16,235.00
JP¥18,010.00
+10.9%
9.6%JP¥21,000.00JP¥16,000.00JP¥20,595.0010
Aug ’24JP¥16,850.00
JP¥17,636.36
+4.7%
11.4%JP¥21,000.00JP¥14,000.00JP¥18,680.0011
Jul ’24JP¥17,075.00
JP¥17,425.00
+2.0%
12.9%JP¥21,000.00JP¥14,000.00JP¥18,570.0012
Jun ’24JP¥17,845.00
JP¥16,769.23
-6.0%
9.5%JP¥20,000.00JP¥14,000.00JP¥19,060.0013
May ’24JP¥14,500.00
JP¥16,138.46
+11.3%
6.3%JP¥18,000.00JP¥14,000.00JP¥18,435.0013
Apr ’24JP¥14,560.00
JP¥16,323.08
+12.1%
7.2%JP¥18,000.00JP¥14,000.00JP¥18,830.0013
Mar ’24JP¥13,225.00
JP¥16,323.08
+23.4%
7.2%JP¥18,000.00JP¥14,000.00JP¥19,935.0013
Feb ’24JP¥13,785.00
JP¥16,650.00
+20.8%
9.5%JP¥20,000.00JP¥14,000.00JP¥18,550.0014
Jan ’24JP¥12,705.00
JP¥16,784.62
+32.1%
9.0%JP¥20,000.00JP¥14,500.00JP¥17,625.0013
Dec ’23JP¥14,270.00
JP¥17,023.08
+19.3%
11.1%JP¥21,100.00JP¥14,500.00JP¥16,465.0013
Nov ’23JP¥13,705.00
JP¥17,007.69
+24.1%
11.1%JP¥21,100.00JP¥14,500.00JP¥15,120.0013

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies